Blockade of complement activation product C5a activity using specific antibody attenuates intestinal damage in trinitrobenzene sulfonic acid induced model of colitis

Guojiang Chen(Beijing Institute of Education), Yan Li(Sichuan University), Xudong Gao(Shanxi Medical University), Bing Shen(Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences), Huihui Wang(Yangzhou University), Jianan Wang(Second Affiliated Hospital of Zhejiang University), Yan Dou(Chinese PLA General Hospital), Gencheng Han(Capital Medical University), Yuemei Yang(Tianjin University), Renfeng Guo, Liyan Wang(Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences), Xiao He(Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences), Xinying Li(Central South University), Renxi Wang(Shandong University)
Laboratory Investigation
November 23, 2010
10.1038/labinvest.2010.183
Cited by 43

Related Papers

Enhanced Cardioprotection by Human Endometrium Mesenchymal Stem Cells Driven by Exosomal MicroRNA-21
|Stem Cells Translational Medicine|2016|276
Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer
|Cancer Cell|2023|218
Mechano-regulation of Peptide-MHC Class I Conformations Determines TCR Antigen Recognition
|Molecular Cell|2019|169
Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway
|Immunobiology|2011|166
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Respiratory Medicine|2022|143